• Explore /
  • Poster
  • / FRACTION (Fast Real-time Assessment of Combination Therapies in Immuno-ONcology)-gastric cancer (GC): A randomized, open-label, adaptive, phase 2 study of nivolumab in combination with other immuno-oncology (IO) agents in patients with advanced GC.

FRACTION (Fast Real-time Assessment of Combination Therapies in Immuno-ONcology)-gastric cancer (GC): A randomized, open-label, adaptive, phase 2 study of nivolumab in combination with other immuno-oncology (IO) agents in patients with advanced GC.

Abstract Poster

Authors

null

Praveen Aanur

Bristol-Myers Squibb, Princeton, NJ

Praveen Aanur , Martin Gutierrez , Ronan Joseph Kelly , Jaffer A. Ajani , Geoffrey Yuyat Ku , Crystal Shereen Denlinger , Thomas J. George Jr., Megan Wind-Rotolo , Xiaowei Guan , Manish Gupta , Timothy P. Reilly , Paula M. Fracasso

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Esophageal or Gastric Cancer

Clinical Trial Registration Number

NCT02935634

Citation

J Clin Oncol 35, 2017 (suppl; abstr TPS4137)

DOI

10.1200/JCO.2017.35.15_suppl.TPS4137

Abstract #

TPS4137

Poster Bd #

126a

Abstract Disclosures

Similar Posters

First Author: Salah-Eddin Al-Batran

First Author: Michael B. Atkins

First Author: Ciara Conduit

First Author: Nadja M Meindl-Beinker